Clinical trials: Disabilities Multiple
Multiple Sclerosis, Relapsing-Remitting
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
In the course of therapy escalation, the multiple sclerosis (MS) subjects with high activity of disease receive mainly mitoxantrone.
- Trial name
- REMAIN (NCT01142466)
- Testing
- Interferon beta-1a (Rebif)
- Volunteers
- 30 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Fragile X Syndrome (FXS), Idiopathic Intellectual Developmental Disorder (IDD)
Neuroimaging GABA Physiology in Fragile X Syndrome
The investigators wish to compare the brain distribution of GABA(A) receptors and GABA levels in young adult males with Fragile X Syndrome compared to idiopathic intellectual developmental disorder.
- Trial name
- NCT04308954
- Testing
- [18F]flumazenil
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Down Syndrome
Promoting Health Through Parent Empowerment and the Activation of Routines (PrO-PEAR)
This study will examine the feasibility of the Promoting Health through Parent Empowerment and the Activation of Routines (Pro-PEAR) intervention using a open case-series for intervention optimization followed by a pilot RCT in…
- Trial name
- Pro-PEAR (NCT05020366)
- Testing
- Promoting Health through Parent Empowerment and the Activation of Routines, Enhanced Usual Care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Cornelia De Lange Syndrome
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment
The study "Cornelia de Lange Syndrome: assessing positive effects of Lithium treatment - CLoSER" aims to evaluate the effectiveness on behavioral modifications of lithium carbonate therapy in patients with Cornelia de Lange…
- Trial name
- CLoSER (NCT06789783)
- Testing
- Lithium Carbonate Capsule
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- University of Milan
Prader-Willi Syndrome
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management.
- Trial name
- NCT05322096
- Testing
- RGH-706
- Where
- 23 sites in United States, Czechia and 3 more
- Volunteers
- 39 people
- Sponsor
- Gedeon Richter Plc.
Down Syndrome
Augmentative and Alternative Communication (AAC) and Lexical Gain in Children With Down Syndrome
Children with Down syndrome (DS) have language development particularities that have negative effects in the communication capacity. By this way, Augmentative and Alternative Communication (AAC) is indicated to this population.
- Trial name
- NCT00689988
- Testing
- speech-language therapy with AAC intervention
- Where
- Brazil
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Down Syndrome, Fetal Aneuploidy
Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
- Trial name
- NCT01429389
- Where
- 14 sites in United States, Canada
- Volunteers
- 2,000 people
- Sponsor
- Sequenom, Inc.
Older Adults, ICU
Prognostic Modelling for Prediction of Mortality and Functional Disability in Critically-ill Elderly Patients
Prospective observational study recruiting elderly patients of 60 years and above admitted to Intensive Care Unit (ICU), to study multiple domains of biomarkers ability to predict mortality of patients during intensive care unit…
- Conditions
- Older Adults, ICU, Mortality Prediction, Functional Disability After ICU
- Trial name
- MYELDERLYICU (NCT06163976)
- Where
- 4 sites in Malaysia
- Volunteers
- 329 people
- Sponsor
- Clinical Research Centre, Malaysia